Resources
About Us
Home Report
Store
Epigenetics Market
Epigenetics Market Size, Share, Forecast, & Trends Analysis by Offering (Kits, Reagents, Instruments, Software) Method (DNA Methylation, PCR, Chromatin Analysis, RNA Modification), Application (Oncology, Non-oncology) End User - Global Forecast to 2031
Report ID:MRHC - 104945 Pages: 208 Jul-2024 Formats*: PDF Category: Healthcare Delivery: 24 to 48 HoursEpigenetics Market Size & Forecast
The Epigenetics Market is projected to reach $6.33 billion by 2031 at a CAGR of 15.7% from 2024 to 2031. Epigenetics is the mechanism of phenotypic alteration without permanent genotypic change, which occurs through chromatin modification, DNA methylation, histone modification, chromatin-regulating proteins, and non-coding RNAs. These modifications play a significant role in developing and progressing several oncological and non-oncological diseases. Thus, epigenetic changes are of value in diagnostic and prognostic terms. On the other hand, with the development of personalized medicines and targeted treatment approaches, treatment strategies targeting abnormal epigenetic changes are becoming a promising area for many diseases.
The growth of the epigenetics market is driven by the rising incidence of chronic diseases due to the rising aging population, the increasing prevalence of cancer, rising pharmaceutical R&D expenditures, the increasing focus on epigenetics in drug discovery & development, and the declining costs of genome sequencing. However, the lack of skilled professionals restrains the growth of this market.
The growing applications of epigenetics in non-oncology diseases and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the stakeholders in this market. However, standardization concerns associated with epigenetics procedures and the limited applications of epigenetics in toxicology are major challenges to market growth.
Click here to: Get Free Sample Pages of this Report
Epigenetics Market Growth Drivers
Rising Incidences of Chronic Diseases due to Growing Geriatric Population
The rising incidence of chronic diseases due to growth in the global aging population supports the growth of this market. As per United Nations data, the percentage of the population aged 65 years or over is increasing globally. In 2022, about 9.7% of the global population was aged 65 years or over. This number is expected to increase to 11.7% in 2030 and 16.4% in 2050. People from the older population have reduced immunity and weakened body systems, making them susceptible to chronic diseases, including cardiovascular diseases (CVD), neurological disorders, cancer, and metabolic disorders, among others. Epigenetic modifications, such as DNA methylation, histone modification, and chromatin changes, can cause these diseases. Thus, epigenetic analysis plays an important role in the diagnosis and treatment of chronic diseases.
Cancer is a major cause of death and a prominent obstacle to improving life expectancy in every country worldwide. According to the International Agency for Research on Cancer (IARC), new cancer cases are expected to increase from 19.2 million in 2020 to 24.5 million in 2030. In addition, mortalities from cancer are expected to increase from 9.9 million in 2020 to 12.9 million in 2030. Thus, the increasing prevalence of cancer and genetic disorders is expected to boost the adoption of epigenetic solutions in hospitals & clinical settings.
Growing Utilization of Epigenetic Analysis in Disease Diagnostics and Precision Medicine
The utilization of epigenetic analysis is growing in precision medicine. Advancements in epigenetic analysis are changing how doctors diagnose and treat cancer. New targeted cancer treatments that use genomic data to provide patient-specific treatments are known as precision oncology. It involves the molecular profiling of cancer cells to identify targetable alterations, also known as biomarkers. Quick and reliable sequencing of multiple genes at once is possible with epigenetic analysis. Epigenetic analysis has helped develop precision medicine, which involves tailoring treatments based on disease-causing molecular/epigenetic changes in a person’s body. While epigenetic analysis is used in various scenarios, oncologists are currently using it to sequence patients’ biopsy samples to determine the right medicines that can target the abnormalities driving tumor growth.
Epigenetics is increasingly being used for genomic profiling in targeted cancer applications due to the decreasing costs and turnaround times, improvements in bioinformatics analyses, and the harmonization of knowledge bases to facilitate the clinical interpretation of genomic results. Thus, the growing utilization of genetic analysis in disease diagnostics and precision medicine is expected to drive the growth of this market during the forecast period.
Epigenetic Market Opportunity
Government Initiatives Supporting Large-scale Genomic Sequencing Projects
The availability of advanced sequencing technologies has lowered sequencing costs and significantly reduced the time required for genome sequencing. With the availability of safe and accurate genetic tests, governments around the world aim to promote their use for better healthcare management by investing in genomic research. For instance,
-
According to a report by the Commonwealth of Australia published in February 2024, the Genomics Health Futures Mission invested USD 500.1 million in genomic research. This investment aims to deliver better testing, diagnostics, and treatment.
- In October 2023, the Government of Canada invested USD 15 million for creating a Pan-Canadian Genome Library which allows easier sharing of genomic data across the country.
- In December 2022, the Government of the U.K invested USD 217 million to boost genomic research.
These initiatives are expected to support the growth of genomic research which is further expected to offer significant opportunities for the growth of the market.
Growing Use of Epigenetics in Non-oncology Applications
Cardiovascular diseases (CVDs) are the leading cause of death globally, particularly in developed countries such as the U.S. As per data from the British Heart Foundation, globally, around 620 million people had heart and circulatory diseases as of June 2023, a substantial increase from 530 million in 2019. This increase is attributed to unhealthy lifestyles, growth in the aging population, and improved rates of survival from heart attacks and strokes. According to the American Heart Association (AHA), in 2021, heart disease was the leading cause of mortality in the U.S., accounting for approximately one of every three deaths. Also, a rise in the incidence of CVDs, the prevalence of cigarette smoking and obesity, and decreased participation in physical activities were observed among teenagers in the U.S. The highest number of CVD deaths was recorded in China, followed by India, Russia, the U.S., and Indonesia.
Several epigenetic mechanisms, such as DNA methylation, histone modification, and noncoding RNA, help alter cardiovascular homeostasis and impact cardiovascular or neurological disorders. For instance, the abnormal methylation status of candidate genes is involved in the mechanism and development of cardiovascular diseases. It can be used as a marker to assess cardiovascular disease progression. Also, DNA methylation and hydroxymethylation in humans show differences in 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) levels, which are associated with neural processes during the evolution of the human brain. Such epigenetic mechanisms help understand the changes in normal genetic or cellular responses, supporting the early diagnosis & treatment of disorders.
Epigenetics Market Analysis: Key Findings
By Offering: In 2024, the Kits & Reagents Segment to Dominate the Epigenetics Market
Based on offering, the epigenetics market is segmented into kits & reagents, services, and software. In 2024, the kits & reagents segment is expected to account for the largest share of over 69% of the epigenetics market. The segment’s large market share is attributed to the increasing adoption of epigenetics kits & reagents due to innovations and the benefits offered, the increasing prevalence of various chronic diseases such as cancer, and the frequent and repetitive usage of kits & reagents for epigenetic analyses. Kits & reagents are used to study epigenetics through chromatin analysis, histone analysis, DNA methylation, and sequencing, among other methods. Kits are ready-to-use assays that include components such as primers, controls, columns, buffers, beads, inhibitors, and antibodies, depending on the method used for analysis. Reagents are sold separately and can be used in different concentrations depending on the requirements of the procedure/analysis.
By Method: In 2024, the DNA Methylation Segment to Dominate the Epigenetics Market
Based on method, the epigenetics market is segmented into DNA Methylation, Histone Modification, RNA Modification, Polymerase Chain Reaction, Chromatin Analysis, Sonication, and Other Methods. In 2024, the DNA Methylation segment is expected to account for the largest share of the epigenetics market. The segment’s large share is attributed to the increasing incidence of cancer and technological advancements in PCR, sequencing, and chip-based detection, enabling quick execution and sequencing of specific regions of interest at low costs. In addition, the increasing focus on reducing costs associated with lengthy research and product approval processes also supports the segment’s large share. DNA methylation is further sub-segmented into bisulfite conversion, high-resolution melt (HRM) analysis, immunoprecipitation, and other DNA methylation methods.
By Application: In 2024, the Oncology Segment to Register the Fastest Growth During the Forecast Period
Based on application, the epigenetics market is segmented into oncology and non-oncology. The oncology segment is expected to register the fastest growth of 16.4% during the forecast period. The segment’s growth is attributed to the rising number of cancer cases, government initiatives to raise awareness about cancer, and advances in cancer research. According to the International Agency for Research on Cancer (IARC), new cancer cases are expected to increase from 19.2 million in 2020 to 24.5 million in 2030. Also, mortalities from cancer are expected to increase from 9.9 million in 2020 to 12.9 million in 2030. Manipulating an epigenetic target on cancer cells can make these cells more susceptible to anti-cancer drugs, including chemotherapy, offering a more personalized cancer treatment.
By End User: In 2024, the Pharmaceutical and Biotechnology Companies Segment is Expected to Account for the Largest Share of the Market
Based on end user, the epigenetics market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, and Hospitals & Diagnostic Laboratories. In 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the epigenetics market. The segment’s large market share is attributed to the rising demand for research-related products, the increasing incidence of chronic diseases, rising R&D expenditure of pharmaceutical & biotechnology companies, technological advancements in epigenetics, and the introduction of new epigenetics products for chronic and rare diseases. Epigenetics enables pharmaceutical & biotechnology companies to identify and validate disease interactions and mechanisms that can be used in developing new diagnostic tests and therapies. Epigenetic markers are measurable indicators of a biological state or process that can be used to diagnose, monitor, or predict the progression of a disease and identify changes in gene expression, genetic variations, or epigenetic modifications associated with a particular disease or condition.
Geographical Analysis
In 2024, North America is expected to account for the largest share of over 50.1% of the epigenetics market. The factors attributed to the large share are the strong focus of local companies on product launches and enhancements, the presence of key players, the established healthcare system, the growing number of chronic diseases, and the rising geriatric population. According to the U.S. Census Bureau and Population Estimates and Projections, the geriatric population in the U.S. is projected to reach over 80 million in 2040 from 56.1 million in 2020. As this population group is particularly prone to several infectious and chronic diseases due to weakened immune systems, the number of people with chronic diseases is expected to increase.
Epigenetics Market: Key Companies
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presence, and key strategic developments adopted by leading market players in this market in the last three to four years. The key players profiled in the epigenetics market are Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), New England Biolabs (U.S.), Epigentek Group Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Active Motif (U.S.), and Zymo Research Corporation (U.S.).
Epigenetics Industry Overview: Latest Developments from Key Industry Players
-
In June 2023, Merck KGAA (Germany) expanded its production capacity for highly purified reagents at a site in Nantong, China. This helped the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons.
-
In March 2023, Illumina, Inc. (U.S.) launched its Illumina Complete Long Read Prep, Human, a high-performance, long read, whole genome sequencing assay compatible with NovaSeq 6000, NovaSeq X Plus, NovaSeq X, and Sequencing Systems. This assay also simplifies workflow with reduced DNA requirements compared to long-read offerings.
- In September 2022, Illumina, Inc. (U.S.) launched its NovaSeq 6000 Dx, the first FDA-registered and CE-marked in vitro diagnostic (IVD) high-throughput sequencer, along with Illumina Complete Long-Reads, XLEAP-SBS Chemistry, NextSeq 1000/2000 Roadmap, and NovaSeq X Series (NovaSeq X and NovaSeq X Plus).
- In February 2022, New England Biolabs (U.S.) partnered with EpiCypher, Inc. (U.S.) to co-develop a library prep kit optimized for performance with their CUTANA CUT&RUN epigenomic assays.
Epigenetics Market: Research Summary
|
Particulars |
Details |
|
Number of Pages |
208 |
|
Format |
|
|
Forecast Period |
2024-2031 |
|
Base Year |
2023 |
|
CAGR |
15.7% |
|
Estimated Market Size (Value) |
$6.33 billion by 2031 |
|
Segments Covered |
By Offering
By Method
By Application
By End User
|
|
Countries Covered |
North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, India, and Rest of Asia-Pacific), Latin America and Middle East & Africa |
|
Key Companies |
The key players operating in the global epigenetics market are Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), New England Biolabs (U.S.), Epigentek Group Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Active Motif (U.S.), and Zymo Research Corporation (U.S.). |
Key questions answered in the epigenetics market report:
The global epigenetics market report covers qualitative analysis and market sizing based on therapy type, device type, substance involved, application, and end user. This report involves analyzing various segments of the epigenetics market at the regional and country levels. The report also offers insights on factors impacting market growth, factor analysis, case studies, regulatory analysis, pricing analysis, and Porter’s five forces analysis.
The global epigenetics market is projected to reach $6.33 billion by 2031, at a CAGR of 15.7% from 2024 to 2031.
Among all the offerings studied in this report, the kits & reagents segment is estimated to account for the largest share of the epigenetics market in 2024 due to the increasing prevalence of various chronic diseases, such as cancer, and the frequent & repetitive usage of kits & reagents for epigenetic analyses.
Among all the methods studied in this report, the DNA Methylation segment is projected to gain more traction in the epigenetics market.
The growth of the epigenetics market is driven by the rising incidence of chronic diseases due to the aging population, the increasing prevalence of cancer, rising pharmaceutical R&D expenditures, the increasing focus on epigenetics in drug discovery and development, and the declining costs of genome sequencing. Moreover, the growing applications of epigenetics in non-oncology diseases and government initiatives supporting large-scale genomic sequencing projects are expected to generate growth opportunities for the stakeholders in this market.
The key players operating in the global epigenetics market are Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Illumina, Inc. (U.S.), Qiagen N.V. (Netherlands), New England Biolabs (U.S.), Epigentek Group Inc. (U.S.), Pacific Biosciences of California Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), PerkinElmer, Inc. (U.S.), 10X Genomics, Inc. (U.S.), Active Motif (U.S.), and Zymo Research Corporation (U.S.).
Emerging economies in the Asia-Pacific region, including China and India, are expected to offer growth opportunities for the players operating in this market. The growing geriatric population, rising R&D funding from both government and pharmaceutical companies, technological advancements, and growing prevalence of noncommunicable diseases will likely drive the growth of this market.
1. Introduction
1.1. Market Definition & Scope
1.2. Market Ecosystem
1.3. Currency and Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Process of Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research/Interviews with Key Opinion Leaders from the Industry
2.3. Market Sizing and Forecasting
2.3.1. Market Size Estimation Approach
2.3.2. Growth Forecast Approach
2.3.3. Market Share Analysis
2.4. Assumptions for the Study
3. Executive Summary
4. Market Insights
4.1. Overview
4.2. Factors Affecting Market Growth
4.2.1. Market Dynamics
4.2.2. Factor Analysis
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Buyers
4.3.2. Bargaining Power of Suppliers
4.3.3. Threat of Substitutes
4.3.4. Threat of New Entrants
4.3.5. Degree of Competition
4.4. Pricing Analysis
5. Epigenetics Market Assessment—by Offering
5.1. Overview
5.2. Kits & Reagents
5.2.1. Kits & Assays
5.2.2. Antibodies
5.2.3. Proteins & Enzymes
5.2.4. Other Reagents
5.3. Services
5.4. Software
6. Epigenetics Market Assessment—by Method
6.1. Overview
6.2. DNA Methylation
6.2.1. Bisulfite Conversion
6.2.2. High-resolution Melt (HRM) Analysis
6.2.3. Immunoprecipitation
6.2.4. Other DNA Methylation Methods
6.3. Histone Modification
6.4. RNA Modification
6.5. Polymerase Chain Reaction
6.6. Chromatin Analysis
6.7. Sonication
6.8. Other Methods
7. Epigenetics Market Assessment—by Application
7.1. Overview
7.2. Oncology
7.3. Non-oncology
8. Epigenetics Market Assessment—by End User
8.1. Overview
8.2. Pharmaceutical & Biotechnology Companies
8.3. Academic & Research Institutes
8.4. Hospitals & Diagnostic Laboratories
9. Epigenetics Market Assessment—by Geography
9.1. Overview
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific
9.5. Latin America
9.6. Middle East & Africa
10. Competitive Analysis
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Competitive Dashboard
10.4.1. Industry Leaders
10.4.2. Market Differentiators
10.4.3. Vanguards
10.4.4. Emerging Companies
10.5. Market Share Analysis (2023)
10.5.1. Merck KGaA (Germany)
10.5.2. 10X Genomics, Inc. (U.S.)
10.5.3. Thermo Fisher Scientific Inc. (U.S.)
10.5.4. Illumina, Inc. (U.S.)
10.5.5. QIAGEN N.V. (Netherlands)
11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, Strategic Developments, *SWOT Analysis)
11.1. Merck KGaA
11.2. 10X Genomics, Inc.
11.3. Thermo Fisher Scientific Inc.
11.4. Illumina, Inc.
11.5. Qiagen N.V.
11.6. New England Biolabs
11.7. Epigentek Group Inc
11.8. Pacific Biosciences of California Inc.
11.9. Bio-Rad Laboratories, Inc.
11.10. PerkinElmer, Inc.
11.11. Active Motif
11.12. Zymo Research Corporation
(Note: SWOT Analysis Provided is for Top 5 Players in the Market)
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 Healthcare Expenditure as A Percentage of GDP, by Country, 2020 Vs. 2021
Table 2 Number of New Cancer Cases, by Type, 2020 Vs. 2030
Table 3 Incidence of Common Genetic Disorders, 2021
Table 4 Pricing: Epigenetics Antibodies
Table 5 Pricing of Epigenetics Antibodies Based on Method
Table 6 Prices of Epigenetics Kits
Table 7 Global Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 8 Global Epigenetics Kits & Reagents Market, by Product, 2022–2031 (USD Million)
Table 9 Global Epigenetics Kits & Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 10 Key Companies Offering Epigenetics Kits & Assays
Table 11 Global Epigenetics Kits & Assays Market, by Country/Region, 2022–2031 (USD Million)
Table 12 Key Companies Offering Epigenetics Antibodies
Table 13 Global Epigenetics Antibodies Market, by Country/Region, 2022–2031 (USD Million)
Table 14 Key Companies Offering Epigenetics Proteins & Enzymes
Table 15 Global Epigenetics Proteins & Enzymes Market, by Country/Region, 2022–2031 (USD Million)
Table 16 Key Companies Offering Other Epigenetics Reagents
Table 17 Global Other Epigenetics Reagents Market, by Country/Region, 2022–2031 (USD Million)
Table 18 Key Companies Offering Epigenetics Instruments & Accessories
Table 19 Global Epigenetics Instruments & Accessories Market, by Country/Region, 2022–2031 (USD Million)
Table 20 Global Epigenetics Services Market, by Country/Region, 2022–2031 (USD Million)
Table 21 Key Companies Offering Epigenetics Software
Table 22 Global Epigenetics Software Market, by Country/Region, 2022–2031 (USD Million)
Table 23 Global Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 24 Global Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 25 Global Epigenetics Market for DNA Methylation, by Country/Region, 2022–2031 (USD Million)
Table 26 Global Epigenetics Market for Bisulfite Conversion, by Country/Region, 2022–2031 (USD Million)
Table 27 Global Epigenetics Market for High-Resolution Melt (HRM)Analysis, by Country/Region, 2022–2031 (USD Million)
Table 28 Global Epigenetics Market for Immunoprecipitation, by Country/Region, 2022–2031 (USD Million)
Table 29 Global Epigenetics Market for Other DNA Methylation Methods, by Country/Region, 2022–2031 (USD Million)
Table 30 Global Epigenetics Market for Histone Modification, by Country/Region, 2022–2031 (USD Million)
Table 31 Global Epigenetics Market for RNA Modifications, by Country/Region, 2022–2031 (USD Million)
Table 32 Global Epigenetics Market for Polymerase Chain Reaction (PCR), by Country/Region, 2022–2031 (USD Million)
Table 33 Global Epigenetics Market for Chromatin Analysis, by Country/Region, 2022–2031 (USD Million)
Table 34 Global Epigenetics Market for Sonication, by Country/Region, 2022–2031 (USD Million)
Table 35 Global Epigenetics Market for Other Methods, by Country/Region, 2022–2031 (USD Million)
Table 36 Global Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 37 Estimated Number of New Cancer Cases, by Type, 2020 Vs. 2030
Table 38 Global Epigenetics Market for Oncology, by Country/Region, 2022–2031 (USD Million)
Table 39 Global Epigenetics Market for Non-oncology, by Country/Region, 2022–2031 (USD Million)
Table 40 Global Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 41 Global Epigenetics Market for Pharmaceutical & Biotechnology Companies, by Country/Region, 2022–2031 (USD Million)
Table 42 National Institutes of Health Funding, 2020-2024 (USD Million)
Table 43 Global Epigenetics Market for Academic & Research Institutes, by Country/Region, 2022–2031 (USD Million)
Table 44 Global Epigenetics Market for Hospitals & Diagnostic Laboratories, by Country/Region, 2022–2031 (USD Million)
Table 45 Global Epigenetics Market, by Country/Region, 2022–2031 (USD Million)
Table 46 North America: Epigenetics Market, by Country, 2022–2031 (USD Million)
Table 47 North America: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 48 North America: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 49 North America: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 50 North America: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 51 North America: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 52 North America: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 53 U.S. Number of New Cancer Cases, 2021 Vs. 2022
Table 54 U.S.: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 55 U.S.: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 56 U.S.: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 57 U.S.: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 58 U.S.: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 59 U.S.: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 60 Canada: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 61 Canada: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 62 Canada: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 63 Canada: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 64 Canada: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 65 Canada: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 66 Europe: Epigenetics Market, by Country/Region, 2022–2031 (USD Million)
Table 67 Europe: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 68 Europe: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 69 Europe: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 70 Europe: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 71 Europe: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 72 Europe: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 73 Germany: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 74 Germany: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 75 Germany: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 76 Germany: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 77 Germany: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 78 Germany: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 79 France: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 80 France: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 81 France: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 82 France: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 83 France: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 84 France: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 85 Italy: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 86 Italy: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 87 Italy: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 88 Italy: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 89 Italy: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 90 Italy: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 91 U.K.: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 92 U.K.: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 93 U.K.: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 94 U.K.: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 95 U.K.: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 96 U.K.: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 97 Spain: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 98 Spain: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 99 Spain: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 100 Spain: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 101 Spain: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 102 Spain: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 103 Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030
Table 104 Rest of Europe: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 105 Rest of Europe: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 106 Rest of Europe: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 107 Rest of Europe: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 108 Rest of Europe: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 109 Rest of Europe: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 110 Asia-Pacific: Epigenetics Market, by Country/Region, 2022–2031 (USD Million)
Table 111 Asia-Pacific: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 112 Asia-Pacific: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 113 Asia-Pacific: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 114 Asia-Pacific: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 115 Asia-Pacific: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 116 Asia-Pacific: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 117 China: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 118 China: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 119 China: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 120 China: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 121 China: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 122 China: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 123 Japan: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 124 Japan: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 125 Japan: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 126 Japan: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 127 Japan: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 128 Japan: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 129 India: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 130 India: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 131 India: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 132 India: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 133 India: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 134 India: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 135 Estimated Number of New Cancer Cases, by Country, 2020 Vs. 2030
Table 136 Rest of Asia-Pacific: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 137 Rest of Asia-Pacific: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 138 Rest of Asia-Pacific: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 139 Rest of Asia-Pacific: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 140 Rest of Asia-Pacific: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 141 Rest of Asia-Pacific: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 142 Latin America and The Caribbean: New Cancer Cases, 2020 Vs. 2040
Table 143 Latin America and The Caribbean: Percentage of Older Population (65 Years and Above)
Table 144 Latin America: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 145 Latin America: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 146 Latin America: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 147 Latin America: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 148 Latin America: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 149 Latin America: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 150 Middle East & Africa: Percentage of Older Population (65 Years and Above)
Table 151 Africa: Number of New Cancer Cases, 2020 Vs. 2040
Table 152 Middle East & Africa: Epigenetics Market, by Offering, 2022–2031 (USD Million)
Table 153 Middle East & Africa: Epigenetics Kits and Reagents Market, by Product, 2022–2031 (USD Million)
Table 154 Middle East & Africa: Epigenetics Market, by Method, 2022–2031 (USD Million)
Table 155 Middle East & Africa: Epigenetics Market for DNA Methylation, by Type, 2022–2031 (USD Million)
Table 156 Middle East & Africa: Epigenetics Market, by Application, 2022–2031 (USD Million)
Table 157 Middle East & Africa: Epigenetics Market, by End User, 2022–2031 (USD Million)
Table 158 Recent Developments, by Company, 2021–2024
List of Figures
Figure 1 Research Process
Figure 2 Secondary Sources Referenced for This Study
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-Side & Demand-Side)
Figure 6 Market Sizing and Growth Forecast Approach
Figure 7 Global Epigenetics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 8 Global Epigenetics Market, by Method, 2024 Vs. 2031 (USD Million)
Figure 9 Global Epigenetics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 10 Global Epigenetics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 11 Global Epigenetics Market, by Geography
Figure 12 Global Epigenetics Market: Impact Analysis of Market Dynamics
Figure 13 Percentage of Population Aged 65 Years or Over, by Region, 2024 Vs. 2031
Figure 14 Genome Sequencing Costs, 2010–2021 (USD)
Figure 15 Global Pharmaceutical R&D Expenditure, 2012–2026 (USD Billion)
Figure 16 Porter’s Five Forces Analysis
Figure 17 Global Epigenetics Market, by Offering, 2024 Vs. 2031 (USD Million)
Figure 18 Global Epigenetics Market, by Method, 2024 Vs. 2031 (USD Million)
Figure 19 Global Epigenetics Market, by Application, 2024 Vs. 2031 (USD Million)
Figure 20 Number of Medicines in Active Research for Cancer Therapeutics, 2018–2022
Figure 21 Global Epigenetics Market, by End User, 2024 Vs. 2031 (USD Million)
Figure 22 Global Pharmaceutical R&D Expenditure, 2016–2028 (USD Billion)
Figure 23 Global Epigenetics Market, by Geography, 2024 Vs. 2031 (USD Million)
Figure 24 North America: Epigenetics Market Snapshot
Figure 25 U.S.: Number of People with Chronic Diseases, 2005–2030 (In Million)
Figure 26 Europe: Epigenetics Market Snapshot
Figure 27 Italy: Number of Biotechnology Firms, 2010-2021
Figure 28 Asia-Pacific: Epigenetics Market Snapshot
Figure 29 China: Pharmaceutical R&D Expenditure (USD Million)
Figure 30 Key Growth Strategies Adopted by Leading Players, 2021–2024
Figure 31 Epigenetics Market: Competitive Benchmarking by Offering
Figure 32 Epigenetics Market: Competitive Benchmarking, by Region
Figure 33 Competitive Dashboard: Epigenetics Market
Figure 34 Global Epigenetics Market Share Analysis, by Key Players, 2023 (%)
Figure 35 Merck KGaA: Financial Overview (2023)
Figure 36 10x Genomics, Inc.: Financial Overview (2023)
Figure 37 Thermo Fisher Scientific Inc.: Financial Overview (2023)
Figure 38 Illumina, Inc.: Financial Overview (2023)
Figure 39 Qiagen N.V.: Financial Overview (2023)
Figure 40 Pacific Biosciences of California, Inc.: Financial Overview (2023)
Figure 41 Bio-Rad Laboratories: Financial Overview (2023)
Figure 42 PerkinElmer, Inc.: Financial Overview (2023)
Author Name:
Proudly Partnering With Enterprises Around the Globe
Quick Contact
Related Reports
Biomarkers Market - Global Opportunity Analysis And Industry Forecast (2024-2031)
Published Date: May-2024
Animal Genetics Market - Global Opportunity Analysis and Industry Forecast (2024-2031)
Published Date: May-2024
